Naven Health’s Post

One of the mechanisms which need thorough understanding while working with critical care patients.

Data from #PTN studies have contributed to 23 FDA drug label changes. These label changes further our objective of improving dosing and treatments for children by adding information about use in pediatric patients. Read more about our research: https://lnkd.in/e4SvzmQ2

Each phase of clinical development comes with its own challenges and cost considerations, influenced by factors like trial size, scope, and duration. From safety assessments in phase 1 to large-scale efficacy studies in phase 3, discover the strategies that can help you optimize costs without compromising your data quality. https://hubs.li/Q02RrYpc0 #ClinicalTrials #CostOptimization #CRO #ClinicalResearch #SouthernStarResearch

Daily Critical Care Pearls #118: Antithrombotic therapy in ACS 💉 (GP) IIb/IIIa inhibitors use should be considered for bailout if there is evidence of no-reflow or a thrombotic complication during PCI 💉 Intravenous enoxaparin should also be considered as an anticoagulant for PCI in patients with NSTE-ACS in whom subcutaneous (s.c.) enoxaparin was used while awaiting coronary angiography 💉 Intravenous enoxaparin should also be considered as an anticoagulant for PCI in patients with NSTE-ACS in whom subcutaneous (s.c.) enoxaparin was used while awaiting coronary angiography #ivpn #criticalcare #pharmacy #medicine #clinicalpharmacy #pearls

Paediatric Patients Benefit from FDA Approval of NexoBrid for Severe Burns Treatment The FDA has approved NexoBrid by MediWound and Vericel® Corporation for pediatric burn patients, expanding its previous use for adults. The approval was based on positive results from the Phase III Children Innovative Debridement Study, which demonstrated NexoBrid's effectiveness in treating 145 pediatric patients. This breakthrough represents a significant advancement in burn care, offering a safer and less invasive treatment option for young patients. It also highlights the potential of proteolytic enzyme therapies in wound care, with MediWound continuing to innovate with products like EscharEx for chronic wounds. NexoBrid's approval not only transforms pediatric burn care but also solidifies MediWound's role in the evolving wound care industry, which is expected to grow to $38.8 billion by 2030. For more details please click the link! https://lnkd.in/dFUaps5g #marketaccess #reimbursement #pricing #hta #heor #healtheconomics #medicaldevices #pharmaceutical 

Reducing Friction in the Biologic Therapy Journey: Supporting Healthcare Professionals Every Step of the Way Biologic therapies are transformative but come with complexities—specialized administration, strict safety monitoring, and cost concerns that impact healthcare professionals and patients alike. So, how can we, as an industry, make biologic therapy more accessible and less burdensome for healthcare providers? 1. Simplify Education: Offer clear, actionable guidance on administration, dosing, and safety protocols. 2. Streamline Reimbursement: Support with prior authorization and insurance approvals to ease the administrative load. 3. Build Patient Support: Provide tools for patient adherence and education, like co-pay assistance, adherence programs, and support on injection techniques. 4. Enable Multidisciplinary Collaboration: Training resources for the entire care team—nurses, pharmacists, and support staff—make biologic integration seamless. 5. Offer Real-World Evidence: Physicians value data. Comparative studies and real-world outcomes increase confidence and comfort in prescribing biologics. By focusing on these strategies, we can make biologic therapies more accessible, allowing healthcare professionals to focus on what matters most: providing the best possible care for their patients. Let’s work together to make the biologic journey smoother for everyone involved.

New article in Drugs in Context Feasibility and reliability of a quality indicator system for an ambulatory dispensing service Andrea Jetzú Bautista Gómez, Maricela López Orozco, Liliana Barajas Esparza, Hermelinda De la Cruz Durán, Alejandro Chehue Romero, Isis Beatriz Bermudez Camps, ANA MARIA TELLEZ LOPEZ, Laura Cristina López Vargas, María Isabel Valverde Merino, Fernando Martínez Martínez, Ivette Reyes Hernández Article discussing the feasibility and reliability of a quality indicator system for a drug dispensing service for paediatric outpatients in two Mexican hospitals. #drugsincontext #drugdispensing #pharmacology #hospitals #qualityindicator https://lnkd.in/dfVfrtcC

⁉ Donanemab NHS rejection! The recent rejection of #donanemab by NHS highlights a familiar challenge confronted by innovative treatments - cost-effectiveness. The cost of the therapy exceeds NICE's acceptable thresholds, raising concerns about whether it's long-term benefits justify the high upfront costs. Balancing innovation with affordability remains a critical issue for healthcare systems. How can we continue to support accelerated access to innovative treatments while keeping costs sustainable for public healthcare systems? Read more below in my recent post on the topic: https://lnkd.in/dpVvSEGj #pharmaceuticals #biotech #globalhealth #innovation #SyenzaNews

Expert: Implementing Cost-Effective Care Is Essential to Mitigate Financial Toxicity: Using biosimilars and generics as well as getting patients connected with manufacturer copay assistance or grant programs can reduce their out-of-pocket costs. #finance #pharmacy #lifesciences

Hello Life Sciences friends, Please click below to read a blog post from my colleagues entitled: Unpackaging CMS’s HOPPS Proposed Rule and Payments for Diagnostic Radiopharmaceuticals. This post reviews the contours of the proposed rule that would considerably increase reimbursement for certain qualified diagnostic radiopharmaceuticals. #MLLifeSci, #wearemorganlewis